Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plasmatherapy in Septic Shock-induced Coagulopathy
NCT04580563Completed
- Sponsor
- Strasbourg University Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of octaplas lg in coagulopathy and disseminated intravascular coagulation (DIC) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Delays between the diagnosis of coagulopathy and the administration of treatment at Day 2. Started Oct 2020; status: completed.
02
Drugs
octaplas lg
03
Conditions
coagulopathydisseminated intravascular coagulation (DIC)
Beyond the preview
Go deeper on NCT04580563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04580563.